Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock The Motley Fool
Covered in this story
Analyst targets on Pfizer
- Cantor Fitzgerald: at $28.3 · target $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: at $28.3 · target $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: at $28.3 · target $30 by Oct 2027 · Neutral via The Globe and Mail
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 46 stories mentioning Pfizer, the earliest published 28 Apr 2017.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.